Nobuki Sakauchi

Fujisawa, 2518555, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Discovery of CTX-439: A Potent and Selective CDK12 Inhibitor as a Prospective Anti-Cancer Drug.

Discovery of CTX-439: A Potent and Selective CDK12 Inhibitor as a Prospective Anti-Cancer Drug.

Journal: ACS medicinal chemistry letters

Published: March 11, 2026

Discovery of Rogocekib (CTX-712): A Potent and Selective CLK Inhibitor for Cancer Treatment.

Discovery of Rogocekib (CTX-712): A Potent and Selective CLK Inhibitor for Cancer Treatment.

Journal: ACS medicinal chemistry letters

Published: July 04, 2025

Lead Optimization of Influenza Virus RNA Polymerase Inhibitors Targeting PA-PB1 Interaction.

Lead Optimization of Influenza Virus RNA Polymerase Inhibitors Targeting PA-PB1 Interaction.

Journal: Journal of medicinal chemistry

Published: December 14, 2021

Identification of a novel series of potent and selective CCR6 inhibitors as biological probes.

Identification of a novel series of potent and selective CCR6 inhibitors as biological probes.

Journal: Bioorganic & medicinal chemistry letters

Published: June 12, 2018

Identification of 3,4-dihydro-2H-thiochromene 1,1-dioxide derivatives with a phenoxyethylamine group as highly potent and selective α1D adrenoceptor antagonists.

Identification of 3,4-dihydro-2H-thiochromene 1,1-dioxide derivatives with a phenoxyethylamine group as highly potent and selective α1D adrenoceptor antagonists.

Journal: European journal of medicinal chemistry

Published: May 10, 2017

Design, synthesis, and biological evaluation of a novel series of peripheral-selective noradrenaline reuptake inhibitors - Part 3.

Design, synthesis, and biological evaluation of a novel series of peripheral-selective noradrenaline reuptake inhibitors - Part 3.

Journal: Bioorganic & medicinal chemistry

Published: April 26, 2016

Design, synthesis, and biological evaluation of a novel series of peripheral-selective noradrenaline reuptake inhibitors-Part 2.

Design, synthesis, and biological evaluation of a novel series of peripheral-selective noradrenaline reuptake inhibitors-Part 2.

Journal: Bioorganic & medicinal chemistry

Published: April 22, 2016

Discovery of 5-Chloro-1-(5-chloro-2-(methylsulfonyl)benzyl)-2-imino-1,2-dihydropyridine-3-carboxamide (TAK-259) as a Novel, Selective, and Orally Active α1D Adrenoceptor Antagonist with Antiurinary Frequency Effects: Reducing Human Ether-a-go-go-Related Gene (hERG) Liabilities.

Discovery of 5-Chloro-1-(5-chloro-2-(methylsulfonyl)benzyl)-2-imino-1,2-dihydropyridine-3-carboxamide (TAK-259) as a Novel, Selective, and Orally Active α1D Adrenoceptor Antagonist with Antiurinary Frequency Effects: Reducing Human Ether-a-go-go-Related Gene (hERG) Liabilities.

Journal: Journal of medicinal chemistry

Published: March 09, 2016

Design, synthesis and biological evaluation of a novel series of peripheral-selective noradrenaline reuptake inhibitor.

Design, synthesis and biological evaluation of a novel series of peripheral-selective noradrenaline reuptake inhibitor.

Journal: Bioorganic & medicinal chemistry

Published: April 12, 2015

Showing 1-9 of 9

Last Updated: 09/26/2026